2024
Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023.
Lee Y, Chen L, Chew V, Chow E, Deng L, Hunziker W, Lee A, Leong G, Ngeow J, Pervaiz S, Sabapathy K, Skanderup A, Sundar R, Tay Y, Virshup D, Wong S, Tergaonkar V, Tam W. Pushing the Frontiers of Cancer Research: Highlights from the Frontiers in Cancer Science Conference 2023. Cancer Research 2024, 84: 1195-1198. PMID: 38616656, DOI: 10.1158/0008-5472.can-24-0721.Commentaries, Editorials and LettersFRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study)
Ling R, Ueno R, Alamgeer M, Sundararajan K, Sundar R, Bailey M, Pilcher D, Subramaniam A. FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal Of Anaesthesia 2024, 132: 695-706. PMID: 38378383, DOI: 10.1016/j.bja.2024.01.020.Peer-Reviewed Original ResearchConceptsElective surgeryCohort studyMulticentre retrospective cohort studyRetrospective multicentre cohort studyPatients admitted to intensive care unitsAssociated with poor outcomesAssociated with similar effectsAssociated with lower survivalCancer-related surgeryMulticentre cohort studyRetrospective cohort studyLong-term outcomesIntensive care unitAssociated with mortalityPoor outcomeFollow-upICU admissionPrimary outcomeCare unitSurgeryPatientsSurvival informationCancerFrailtyICU
2023
Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients
Li J, Lee M, Peng S, Bin Lee A, Tay R, Chee C, Ho C, Walsh J, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients. European Journal Of Surgical Oncology 2023, 49: e60-e61. PMCID: PMC9941290, DOI: 10.1016/j.ejso.2022.11.202.Peer-Reviewed Original Research
2020
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.Peer-Reviewed Educational MaterialsImmune checkpoint inhibitionGastroesophageal cancerPredictive biomarkersCheckpoint inhibitionRandomized phase III studyImmune checkpoint inhibitor trialsValidation of predictive biomarkersCheckpoint inhibitor trialsPhase III studySubgroup of patientsIII studiesSurvival benefitInhibitor trialsPatient selectionGastroesophagealNovel biomarkersPrecision oncologyCancer treatmentCancerRegulatory approvalImmunotherapyNegative resultsBiomarkersPatientsInhibition
2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar R, Chénard-Poirier M, Collins D, Yap T. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers In Medicine 2017, 4: 39. PMID: 28443282, PMCID: PMC5385461, DOI: 10.3389/fmed.2017.00039.Peer-Reviewed Educational MaterialsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerClinical outcome of advanced non-small cell lung cancerOutcomes of advanced non-small cell lung cancerManagement of advanced non-small cell lung cancerLung cancerPrecision medicineEra of precision medicineClinical trial testingImpact of precision medicineDriver aberrationsClinical outcomesNon-smallAntitumor therapyRegulatory approvalMultiple deficienciesCancerHypothesis-testing studiesDiseaseComplex diseasesMedicineTherapyPatients
2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.Peer-Reviewed Educational MaterialsConceptsPrecision medicineNext-generation sequencingMechanisms of drug resistanceField of immunotherapyManagement of cancer patientsOptimize treatment efficacyAntitumor responseIntertumoral heterogeneityClonal evolutionTargeted agentsMinimal toxicityDrug resistanceCancer patientsTreatment efficacyBiomarker developmentBiomarker discoveryCancer researchCancerCompounds promisesImmunotherapyMedicine
2014
Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer.
Wong A, Sundar R, Ow S, Wang T, Ng T, Chan C, Hartman M, Iau P, Tan S, Zhang B, Thng C, Mogro M, Voon P, Buhari S, Soh I, Goh B, Lee S. Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1060-1060. DOI: 10.1200/jco.2014.32.15_suppl.1060.Peer-Reviewed Original Research